SCHEMBL20119976

SCHEMBL20119976

N#Cc1c[nH]c2nc(Cl)nc(NCc3nccs3)c12

nearest known ligand 0.45

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
CHUK O15111 7/20 0.45
LRRK2 Q5S007 8/20 0.43
MAP3K8 P41279 1/20 0.37
ROCK2 O75116 2/20 0.36
ROCK1 Q13464 2/20 0.36
CDC42BPA Q5VT25 2/20 0.36
CDC42BPB Q9Y5S2 2/20 0.36
HRH4 Q9H3N8 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119881 0.84 HRH4 (0.37) MAP3K8HRH4SMN1; SMN2
SCHEMBL20119563 0.83 HRH4 (0.36) MAP3K8HRH4SMN1; SMN2
SCHEMBL20119647 0.82 HRH4 (0.38) ROCK2HRH4SMN1; SMN2
SCHEMBL20119636 0.78 CHUK (0.59) CHUKLRRK2ROCK2ROCK1CDC42BPA
SCHEMBL22280368 0.78 CHUK (0.51) CHUKLRRK2ROCK2ROCK1CDC42BPA
SCHEMBL20119669 0.76 LRRK2 (0.48) CHUKLRRK2MAP3K8ROCK2ROCK1
SCHEMBL20344047 0.76 CHUK (0.74) CHUKLRRK2
SCHEMBL22280369 0.74 CHUK (0.54) CHUKLRRK2ROCK2ROCK1CDC42BPA
SCHEMBL20119582 0.73 SMN1; SMN2 (0.42) MAP3K8HRH4SMN1; SMN2
SCHEMBL20119906 0.73 SMN1; SMN2 (0.53) CHUKLRRK2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 CHUK 2130/4885LRRK2 3429/4885MAP3K8 3754/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 CHUK 2130/4885LRRK2 3429/4885MAP3K8 3754/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 CHUK 2130/4885LRRK2 3429/4885MAP3K8 3754/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 CHUK 2130/4885LRRK2 3429/4885MAP3K8 3754/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 CHUK 2130/4885LRRK2 3429/4885MAP3K8 3754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.